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Translational perspectives on perfusion–diffusion mismatch in ischemic stroke
Bruce C. V. Campbell1 and I. Mhairi Macrae2*
Magnetic resonance imaging has tremendous potential to illu-
minate ischemic stroke pathophysiology and guide rational
treatment decisions. Clinical applications to date have been
largely limited to trials. However, recent analyses of the major
clinical studies have led to refinements in selection criteria and
improved understanding of the potential implications for the
risk vs. benefit of thrombolytic therapy. In parallel, preclinical
studies have provided complementary information on the evo-
lution of stroke that is difficult to obtain in humans due to the
requirement for continuous or repeated imaging and patho-
logical verification. We review the clinical and preclinical
advances that have led to perfusion–diffusion mismatch being
applied in phase 3 randomized trials and, potentially, future
routine clinical practice.
Key words: diffusion imaging, MRI, penumbra, perfusion imaging, stroke,
thrombolytic therapy
Magnetic Resonance Imaging (MRI) imaging of
acute ischemic stroke in current clinical practice
Although a few centers now have MRI scanners in the emergency
department or can access MRI rapidly for acute stroke patients, the
clinical application of MRI for acute stroke treatment decision
making has to date been fairly limited. The theoretical rationale for
advanced imaging in acute ischemic stroke is to estimate the extent
of potentially salvageable tissue in the‘penumbra’vs. the volume of
‘ischemic core’. Penumbra is a concept defined in the 1970s (1) of
hypoperfused and functionally impaired brain that can regain
normal function if rapidly reperfused but otherwise has a high risk
of progressing to infarction. Penumbra is the conceptual basis of
all reperfusion therapies, and its existence is made possible by
collateral flow via alternative blood flow routes, predominantly
through the circle of Willis or leptomeningeal anastomoses (2).
Ischemic core is defined as tissue that has been irreversibly
damaged and will progress to infarction regardless of whether it is
reperfused (3). Positron emission tomography (PET) has been
used to identify these tissue states in vivo (4), and the hope for
perfusion–diffusion MRI has been to provide more accessible
estimates of ischemic core and penumbra in clinical practice.
Currently, the only proven reperfusion therapy is intravenous
tissue plasminogen activator (tPA) administered within 4·5 h
of stroke onset in patients selected using clinical criteria and
noncontrast CT to exclude hemorrhage. Existing data using this
approach suggest minimal benefit beyond 4·5 h (5). However,
studies such as DEFUSE (6), EPITHET (7), and DEFUSE-2 (8)
have demonstrated the potential for selecting patients who may
benefit from reperfusion therapies beyond the current 4·5 h time-
frame. The concept of perfusion–diffusion mismatch selection is
now being tested in phase 3 trials such as EXTEND (9) and
ECASS4-EXTEND. Some centers have been using extended time
window MRI-based mismatch selection in clinical practice and
have reported safety and clinical outcomes comparable with stan-
dard sub-4·5 h tPA patients in uncontrolled case series (10). This
section of the review will address recent refinements in mismatch
theory that are relevant to its clinical application.
Diffusion imaging
Diffusion imaging is immensely powerful as a diagnostic tool in
suspected stroke. It becomes abnormal within minutes of stroke
onset (11) and has far greater sensitivity and specificity than any
other current modality (12). Diffusion imaging is the key param-
eter to estimate irreversibly injured tissue in perfusion–diffusion
mismatch or, for that matter, MRA-diffusion (13) or clinical-
diffusion mismatch (14,15). The extent and location of the base-
line diffusion lesion may be at least as important to clinical
outcome after reperfusion as the volume of mismatch (16–18).
Patients with large baseline diffusion-weighted imaging (DWI)
lesions very rarely achieve a favorable clinical outcome, regardless
of the success of reperfusion attempts. Indeed, these patients may
be at greater risk of harm from reperfusion – the concept of
‘malignant’ or ‘futile’ profile (6). Current mismatch definitions
include a maximum DWI lesion volume (e.g. <70 ml) in addition
to the mismatch ratio and absolute volume of mismatch (8,9).
Considerable literature has evolved around the question of
whether diffusion lesion reversal is a relevant clinical phenomenon
(19). Much of this was confounded by inadequate attention to in-
farct atrophy, temporary postreperfusion reversal, and the milder
spectrum of gliotic changes on follow-up Fluid Attenuated Inver-
sion Recovery (FLAIR) imaging. Although the cytotoxic edema
represented by diffusion restriction may be theoretically reversible
(20), in clinical practice diffusion lesion reversal is rare. This has
been studied predominantly beyond three-hours from onset when
most stroke MRI is performed (21,22). One recent study that
included 114 patients with pretreatment diffusion MR obtained
<3 h from stroke onset found that 17% had reversal of >10 ml and
>10% of the baseline lesion volume when reassessed at 24 h (23).
Another similar sized but less quantitative study found predomi-
nantly temporary reversal in some cases on post-thrombolysis
DWI with return of the lesion on FLAIR at seven-days (22). Tem-
porary reversal is more common immediately after reperfusion,
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although the time–course in humans is not well characterized (24).
This is analogous to work in rats where 30 min of middle cerebral
artery (MCA) occlusion lead to a diffusion lesion that completely
vanished after reperfusion but later returned (25). In the same
study, 10 min of MCA occlusion lead to a diffusion lesion that
permanently disappeared. Histologically, however, there was neu-
ronal loss indicating that the tissue salvage was incomplete. This
incomplete tissue salvage in regions of normal FLAIR appearance,
traditionally regarded as outside the infarct, has also been identi-
fied in man with reduced flumazenil binding using PET (26) and
reduced magnetization transfer ratio using MRI (27). Thus, the
common binary approach to defining irreversible injury using
imaging, although pragmatic, is somewhat simplistic.
The best technique to measure diffusion lesion volume remains
controversial. Single apparent diffusion coefficient (ADC) thresh-
olds have been proposed but require significant postprocessing to
achieve reasonable sensitivity while maintaining specificity as
there is considerable overlap in the distribution of ADC values
between injured and normal brain (28). The optimal ADC thresh-
old may also vary with time from stroke onset (29). Although
milder decreases in ADC are observed at the periphery of the
lesion, these seem not to be salvaged in many cases, even with
rapid reperfusion (24). For the purposes of automated segmen-
tation, a combination of absolute ADC and relative B1000 inten-
sity provides a reasonable approximation (30). However, for the
greatest accuracy in research studies, we currently favor manual
outlining of the ‘maximal visual extent’ of B1000 abnormality
using careful windowing (24,31).
Perfusion imaging (PI) and the extent of
ischemic penumbra
The survival of ischemic penumbra depends on the quality of
collateral flow available to bypass an arterial occlusion. Collateral
flow can occur via the circle of Willis or via leptomeningeal anas-
tomoses between anterior cerebral artery (ACA), posterior cere-
bral artery (PCA) and the MCA. In laboratory animals, cerebral
blood flow thresholds have been derived that have a time-
dependent association with tissue viability (32). Studies using
PET in a limited number of human patients with a variable degree
of stroke acuity have suggested that similar relative thresholds,
corresponding to a penumbra range of cerebral blood flow (CBF)
∼17–22 ml/100 g/min, apply in man (33–35). Given the practical
limitations of PET for clinical use, MRI dynamic susceptibility-
weighted contrast PI has been applied.
Interestingly, delay-based parameters such as Tmax and TTP
(time to peak of the deconvolved tissue residue function and raw
concentration-time curve, respectively) have seemed more robust
predictors of infarct risk than the relative CBF measures provided
by MRI (36,37). Increased TTP and Tmax reflect the delay and
dispersion incurred by flow travelling through collateral path-
ways. Simplistically, the longer the delay, the further the blood had
to travel down the collateral vessels and the greater the risk of flow
becoming inadequate to sustain tissue viability (38).
A key area of interest has been to distinguish tissue destined for
infarction in the absence of reperfusion (one method of defining
the ‘ischemic penumbra’) from that which will survive indefi-
nitely even in the absence of reperfusion (so-called ‘benign
oligemia’). It has become clear that tissue experiencing mild
degrees of perfusion delay (e.g. <4 s) at the periphery of the
perfusion lesion almost never proceeds to infarction. Even with
severe delays (e.g. Tmax >10 s) the risk of infarction without
reperfusion is only around 70% (38). Multiple lines of evidence
from PET correlation (37), xenon–CT correlation (39), and
follow-up studies in patients without reperfusion (40,41) have
suggested a delay of >4–6 s as the best threshold to define the
tissue most likely to be at risk in an average patient (Fig. 1).
Precisely predicting the final infarct in an individual patient
from a single snapshot of perfusion is probably impossible as
stroke is a dynamic process with shifts in clot location and fluc-
tuations in collateral flow (42). However, thresholding the perfu-
sion lesion to exclude mild peripheral regions has been a
significant advance in improving the relationship of mismatch
volume with clinical response to reperfusion. A Tmax >6 s perfu-
sion threshold was used in DEFUSE 2 (8), which confirmed the
benefits of reperfusion in patients with mismatch beyond 4·5 h
and is also employed in the ongoing EXTEND trial (9).
Defining mismatch
Early definitions of perfusion–diffusion mismatch used a mis-
match ratio >1·2, which was an arbitrary choice based on the
minimum visually evident difference in volume of two spheres.
This criterion was combined with a minimum mismatch volume
of 10 ml to avoid classifying ‘mismatch’ in very small lesions in the
DEFUSE (6) and EPITHET (7) studies. Both studies used a gen-
erous definition of the perfusion lesion (Tmax ≥2 s), which lead to
relatively high proportions of patients with mismatch (86% in
EPITHET). Subsequent analyses emphasized the strong relation-
ship of more stringent perfusion thresholds and/or higher mis-
match ratios with improved response to reperfusion (41–44). As
discussed above, the use of a Tmax >6 s threshold has been sup-
ported by PET and EPITHET–DEFUSE pooled sub-analyses. The
recently published DEFUSE 2 study used a mismatch ratio >1·8,
absolute mismatch volume >15 ml, and baseline DWI lesion
volume <70 ml to define ‘target mismatch’ in patients about to
undergo open label intra-arterial reperfusion therapy. Target mis-
match patients had significantly better clinical and radiological
outcomes if reperfusion was achieved compared with those in
whom reperfusion therapy failed. The degree of reperfusion in
these patients was directly related to the rate of good clinical
outcome. In contrast, patients without target mismatch demon-
strated no difference in outcome between reperfusion and non-
reperfusion groups (8). The ongoing EXTEND randomized trial
of tPA/placebo is using similar criteria (mismatch ratio >1·2, mis-
match volume >10 ml, and DWI lesion volume <70 ml) to select
patients 4·5–9 h after stroke onset or with wake-up onset stroke
who may benefit from reperfusion (9). The importance of more
selective mismatch definitions was recently highlighted in second-
ary analysis of the DIAS trial, which used visual assessment of
perfusion–diffusion mismatch to select patients for thrombolysis
with desmoteplase. This lead to the inclusion of many patients
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with small lesions, and the primary analysis was negative.
However, reanalysis requiring mismatch of >60 ml demonstrated
clear benefits of desmoteplase on clinical outcome (45).
An alternative approach to mismatch (46) was used in the
recently published MR-RESCUE study (47). The investigators
developed a complex multiparametric equation including DWI,
ADC and several perfusion parameters to estimate the tissue likely
to have already suffered irreversible injury at baseline. This
method was based on the belief that DWI lesion reversal is an
important issue. ‘Mismatch’ was defined using a volume of
multiparametric-derived ‘irreversible injury’ <90 ml and <70% of
perfusion lesion volume defined by Tmax >4 s. This selection
approach did not lead to a positive trial result although the intra-
arterial device intervention tested had limited efficacy in inducing
recanalization and reperfusion. Patients with ‘mismatch’ did have
better outcome in the presence of recanalization (assessed rather
late at seven-days) but a similar trend was observed in nonmis-
match patients, the reasons for which remain unclear (48).
Mismatch and vessel occlusion
Although mismatch can be considered in isolation, the ‘dual
target’ combination of mismatch and major vessel occlusion has
been proposed as a more powerful way to identify patients who
will respond favorably to reperfusion. This is especially pertinent
in trials, where power to detect a difference in good functional
outcome with reperfusion may be greatest in patients with the
severe baseline clinical deficits generally associated with major
vessel occlusion. However, intravenous lytic agents are less effec-
tive in patients with major vessel occlusion, and this may coun-
terbalance the benefits of dual target selection. Vessel occlusion is
particularly relevant to intra-arterial clot retrieval therapies that
are generally confined to the larger vessels. Mismatch has been
argued to be less relevant in this context with the combination of
vessel occlusion and small baseline DWI lesion proposed as
simpler and equally useful in predicting response to therapy. In
reality, the treatment decisions with either approach are usually
concordant. However, mismatch is a more generalizable concept
that may assist decision making when the baseline DWI lesion is
moderately large and in patients without major vessel occlusion.
Perfusion data may also provide extra information on treatment
risk (49–52) and perhaps the probability of infarct expansion in
the absence of reperfusion (38).
This review has not discussed CT perfusion, but this debate
becomes irrelevant when CT is used as the same perfusion data
are used to estimate both ischemic core and penumbra volumes
and, in many cases, reconstruct dynamic angiography to assess
vessel occlusion.
Fig. 1 Example of perfusion MRI in an acute ischemic stroke patient. Time to Peak (TTP) map generated by manufacturer’s software demonstrates a clear
abnormality in the right middle cerebral artery territory. However, without thresholding it is difficult to distinguish ‘benign oligemia’ from tissue at risk of
infarction. The Tmax map (RAPID, Stanford University) quantifies the perfusion delay. Use of a Tmax >6 s threshold reduces the overestimation of tissue
at risk, as seen when compared to the day 30 FLAIR in this patient who did not receive reperfusion therapy. MRI: Magnetic resonance imaging.
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One significant pitfall of current mismatch approaches is that
clinical response to reperfusion depends not only on the absolute
mismatch volume but on the functional significance or ‘elo-
quence’ of the affected region. The dichotomous approach to
mismatch, while necessary for clinical trials, is also somewhat
arbitrary and masks a spectrum of pathophysiology. Incorporat-
ing qualitative spatial and functional information will be a key
step in the translation of mismatch from enriching trial popula-
tions to guiding routine treatment for individual stroke patients.
Ideally, the volume and functional role of the mismatch zone vs.
the baseline DWI lesion would be weighed against an individual-
ized assessment of hemorrhage risk.
MRI imaging of acute ischemic stroke: preclinical
studies in rodents
Small animal MRI scanners, typically 7 tesla or higher magnetic
field strength, are increasingly used to study the ischemic brain in
animal stroke models [reviewed by Planas (53)]. Sequences used
for routine clinical MRI, and more recent research techniques,
have been set up on small animal scanners to facilitate ‘bench to
bedside’ and ‘bedside to bench’ translational research. For
example, T2-weighted imaging for identification and quantitation
of final infarct, DWI for acute ischemic injury, PI for perfusion
deficit, diffusion tensor imaging for damage to white matter, T1
imaging with contrast for blood brain barrier breakdown, and
blood oxygen level dependent (BOLD) functional MRI for loss/
return of function. As in clinical research, diffusion and PI are
combined to generate PI/DWI mismatch for identification of
potentially salvageable penumbral tissue.
There are both benefits and limitations associated with imaging
stroke in animal models. One major benefit is the ability to track
the evolution of damage and loss of penumbra by serially scan-
ning over the first hours poststroke. Additionally, animals can
undergo longitudinal study with multiple scanning sessions to
track the consequences of a particular intervention over a number
of weeks poststroke, and this can be combined with behavioral
assessment of functional outcome. The major limitation is that
during scanning, animals are anesthetized so that the head can be
secured to limit movement. Therefore, the one important differ-
ence between clinical and preclinical stroke research is the need
for anesthesia during stroke surgery and imaging. Anesthetics are
known to influence blood pressure, respiration (and blood gases),
cerebral blood flow, brain metabolism and function, and body
temperature (54). Physiological monitoring and artificial respira-
tion with regular blood gas analysis during prolonged scanning
sessions (e.g. ≥6 h) enables physiology to be maintained within
normal limits and the influence these parameters have on pen-
umbra to be controlled.
Ischemic stroke models targeting the MCA have been estab-
lished in a range of animals including gyrencephalic species such
as the cat (55), miniature pig (56), and baboon (57). However,
most imaging studies are carried out on rats, exposed to middle
cerebral artery occlusion (MCAO). Imaging is also possible in
mice (58) and is increasingly being used to phenotype transgenic
mice (59–61).
Stroke is most commonly induced immediately prior to
imaging but can be induced during the scanning session by
occluding the MCA remotely (62,63). Penumbra is identified as
tissue within the perfusion deficit, which has yet to show abnor-
mality on diffusion scans (perfusion/diffusion mismatch). In the
rodent stroke literature, ADC maps are generated from the diffu-
sion data to obtain quantitative images of the diffusion coeffi-
cient. ADC and perfusion thresholds are then applied to define
the borders of the diffusion abnormality and perfusion deficit,
respectively. Relatively few groups have established ADC and per-
fusion thresholds (Table 1), with most rodent mismatch studies
using one of these published thresholds (Table 2). However, it is
important for groups to establish in-house thresholds specific to
rat strain and time-point(s) being investigated as the ADC thresh-
old has been shown to change with time from stroke onset (Li
et al. (66), Table 1) and perfusion thresholds in one rat strain may
not be applicable in other strains (Reid et al. (69), Table 1).
Data from published rodent mismatch studies are building up
knowledge on the amount of penumbral tissue available for
rescue in different rodent stroke models, including those with
stroke-related comorbidity. A number of serial studies have also
provided information on the evolution of damage and loss of
penumbra in the acute period following stroke in the rat
(Table 2).
Diffusion imaging and the acute diffusion lesion
Hyperintensity is already visible between 0 and 10 min after onset
of ischemia on DWI scans when strokes are induced within the
scanner. The intensity and size of the lesion gradually increases
thereafter [0–6 h (62,63)]. The ADC threshold is calculated for a
given time-point poststroke (usually three- to four-hours), with
reference to the final (edema corrected) infarct size. For example,
0·543 × 10−3 mm2/s or 83·5% of the contralateral hemisphere
(excluding ventricles) at three-hour poststroke (65). In the studies
that have derived in-house ADC thresholds, there is generally
good agreement across strains and stroke models (Table 1).
However, the rate of growth of the ADC-defined lesion is more
variable and may depend on the strain of rat and the level of
collateral supply to MCA territory, the size of the lesion on early
scans, and the level of control of physiological variables (e.g.
blood pressure, blood gases, and body temperature).
PI and the perfusion deficit
Most preclinical acute stroke imaging studies now employ arterial
spin labeling (ASL), which does not require contrast agent injec-
tion and provides a direct assessment of CBF (Table 2) rather than
the delay-based parameters, Tmax and TTP, used clinically. Per-
fusion deficits are defined using a similar threshold approach. A
flow threshold is applied that represents the acute CBF or perfu-
sion value that defines a tissue volume equal to final (edema
corrected) infarct. The majority of studies that have defined a flow
threshold have employed ASL (Table 1). Data are more variable
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than for ADC values (e.g. see range of contralateral CBF values,
Table 1) and consequently there is a wider spread in published
flow thresholds.
In the majority of rodent studies, the volume of perfusion
deficit remains relatively constant over the first four- to six-hours
following stroke, with reductions in the mismatch volume reflect-
ing increases in the volume of the ADC lesion (68,72,75,76).
However, in some studies, the perfusion deficit also increases over
time (69,70,77), which could point to a failure of collateral flow.
These studies used spontaneously hypertensive stroke-prone,
Wistar Kyoto and Sprague Dawley rats. In situations where the
perfusion deficit and DWI lesion grow at a similar rate, this could
give the false impression of survival of penumbral tissue as overall
mismatch volume would not change with time.
Penumbra and perfusion/diffusion mismatch
Preclinically, penumbra volume can be assessed using at least
three different methods:
• by simply subtracting the ADC-derived lesion volume from
the perfusion deficit volume at each time-point (volumetric
perfusion–diffusion mismatch with no anatomical coregistration,
most common);
• slice-by-slice delineation of ADC-derived lesion, perfusion
deficit, and mismatch area using coregistration software (e.g.
Image J, U. S. National Institutes of Health, Bethesda, Maryland,
USA) or voxel-based analysis (e.g. Matlab Mathworks, Natick,
Massachusetts, USA); and
• retrospective assessment of penumbra by subtracting the ADC
lesion volume at a given time-point from the final edema-
corrected infarct.
The size and location of penumbra varies according to the thresh-
olds applied and also which of the three approaches is employed
(69). All published studies using these methods have detected a
measureable mismatch volume at early time-points, within the
range presented in Table 2 and which generally reduces in size
over time. Mismatch volume and its rate of loss vary across dif-
ferent normotensive rat strains (Table 2), with studies on rats
with comorbidity (e.g. hypertension) reporting smaller mismatch
volumes (69,71,77). Therefore, available techniques provide the
means to quantify how much penumbral tissue is available for
tissue salvage and to investigate the potential for therapies to save
or extend penumbra life span. However, direct comparison of
mismatch volume between studies is hampered by a lack of stan-
dardization in the rostro-caudal extent of MCA territory covered
by the scans (see Table 2).
Type and depth of anesthesia can influence the temporal
change in the ADC lesion and perfusion deficit and therefore the
assessment of penumbra from DWI/PI or ADC/PI mismatch.
Instances can arise preclinically where mismatch volume is main-
tained (e.g. over a period of four-hours or longer) without inter-
vention. For example, where the ADC lesion volume does not
increase with time (possibly due to tight control of physiological
variables under anesthesia and/or enhanced oxygenation of ven-
tilation gases), or when the size of the perfusion deficit increases
at a similar rate to ADC lesion growth. In permanent MCAO
models, the volume of hypoperfused tissue, detected acutely, can
exceed the final (edema corrected) infarct at 24 h, making thresh-
old setting problematic. One explanation for this may be that the
increase in blood pressure, on withdrawal of anesthesia, causes an
increase in CBF within the ischemic hemisphere such that the
volume of perfusion deficit is reduced and, consequently, more
tissue survives. Therefore, the potential for anesthesia to influence
penumbra size is not inconsiderable and should be taken into
account when interpreting results.
Summary
A number of preclinical centers are now equipped for rodent MRI
research on the ischemic penumbra. What is needed now is for a
consensus to be reached and the optimum protocols for generat-
ing and processing mismatch data standardized across all centers.
Then preclinical MRI will provide a powerful platform to research
the penumbra and test novel therapeutic strategies for tissue
salvage or to prolong its life span, which hopefully will translate to
the clinic. Physiological stability under anesthesia will be key to
interpretation of results and reproducibility of findings across
sites. Clinical application of perfusion–diffusion mismatch has
already entered practice in some centers. However, studies thus far
have had mixed success in demonstrating treatment effects in
patients selected using various mismatch paradigms. As with pre-
clinical work, much has been learned from these experiences
about the importance of thresholding perfusion lesions and stan-
dardizing processing and interpretation. The current generation
of clinical trials in progress provides hope for a future in which
patient treatment can be individualized on the basis of patho-
physiology, illuminated by imaging.
References
1 Astrup J, Siesjö BK, Symon L. Thresholds in cerebral ischemia – the
ischemic penumbra. Stroke 1981; 12:723–5.
2 Shuaib A, Butcher K, Mohammad AA, Saqqur M, Liebeskind DS.
Collateral blood vessels in acute ischaemic stroke: a potential thera-
peutic target. Lancet Neurol 2011; 10:909–21.
3 Wintermark M, Albers GW, Broderick JP et al.; for the Stroke
Imaging Research (STIR) and VISTA-Imaging Investigators. Acute
Stroke Imaging Research Roadmap II. Stroke 2013; doi: 10.1161/
STROKEAHA.113.002015.
4 Heiss W-D. Ischemic penumbra: evidence from functional imaging in
man. J Cereb Blood Flow Metab 2000; 20:1276–93.
5 Lees KR, Bluhmki E, von Kummer R et al. Time to treatment with
intravenous alteplase and outcome in stroke: an updated pooled
analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet
2010; 375:1695–703.
6 Albers GW, Thijs VN, Wechsler L et al. Magnetic resonance imaging
profiles predict clinical response to early reperfusion: the diffusion and
perfusion imaging evaluation for understanding stroke evolution
(DEFUSE) study. Ann Neurol 2006; 60:508–17.
7 Davis SM, Donnan GA, Parsons MW et al. Effects of alteplase beyond
3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation
Trial (EPITHET): a placebo-controlled randomised trial. Lancet
Neurol 2008; 7:299–309.
8 Lansberg MG, Straka M, Kemp S et al. MRI profile and response to
endovascular reperfusion after stroke (DEFUSE 2): a prospective
cohort study. Lancet Neurol 2012; 11:860–7.
9 Ma H, Parsons MW, Christensen S et al. A multicentre, randomized,
double blinded, placebo controlled phase 3 study to investigate
Review B. C. V. Campbell and I. M. Macrae
© 2013 The Authors. International Journal of Stroke published by John Wiley & Sons Ltd
on behalf of World Stroke Organization.
8 Vol ••, •• 2013, ••–••
EXtending the time for Thrombolysis in Emergency Neurological
Deficits (EXTEND). Int J Stroke 2012; 7:74–80.
10 Schellinger PD, Thomalla G, Fiehler J et al. MRI-based and CT-based
thrombolytic therapy in acute stroke within and beyond established
time windows: an analysis of 1210 patients. Stroke 2007; 38:2640–5.
11 Hjort N, Christensen S, Sølling C et al. Ischemic injury detected by
diffusion imaging 11 minutes after stroke. Ann Neurol 2005; 58:
462–5.
12 Schellinger PD, Bryan RN, Caplan LR et al. Evidence-based guideline:
the role of diffusion and perfusion MRI for the diagnosis of acute
ischemic stroke: report of the Therapeutics and Technology Assess-
ment Subcommittee of the American Academy of Neurology. Neurol-
ogy 2010; 75:177–85.
13 Lansberg MG, Thijs VN, Bammer R et al. The MRA-DWI mismatch
identifies patients with stroke who are likely to benefit from reperfu-
sion. Stroke 2008; 39:2491–6.
14 Davalos A, Blanco M, Pedraza S et al. The clinical-DWI mismatch: a
new diagnostic approach to the brain tissue at risk of infarction.
Neurology 2004; 62:2187–92.
15 Lansberg MG, Thijs VN, Hamilton S et al. Evaluation of the clinical-
diffusion and perfusion-diffusion mismatch models in DEFUSE.
Stroke 2007; 38:1826–30.
16 Parsons MW, Christensen S, McElduff P et al. Pretreatment diffusion-
and perfusion-MR lesion volumes have a crucial influence on clinical
response to stroke thrombolysis. J Cereb Blood Flow Metab 2010;
30:1214–25.
17 Yoo AJ, Verduzco LA, Schaefer PW et al. MRI-based selection for
intra-arterial stroke therapy: value of pretreatment diffusion-weighted
imaging lesion volume in selecting patients with acute stroke who will
benefit from early recanalization. Stroke 2009; 40:2046–54.
18 Menezes NM, Ay H, Wang Zhu M et al. The real estate factor: quan-
tifying the impact of infarct location on stroke severity. Stroke 2007;
38:194–7.
19 Kranz PG, Eastwood JD. Does diffusion-weighted imaging represent
the ischemic core? An evidence-based systematic review. AJNR Am J
Neuroradiol 2009; 30:1206–12.
20 Simard JM, Kent TA, Chen M, Tarasov KV, Gerzanich V. Brain oedema
in focal ischaemia: molecular pathophysiology and theoretical impli-
cations. Lancet Neurol 2007; 6:258–68.
21 Chemmanam T, Campbell BC, Christensen S et al. Ischemic diffusion
lesion reversal is uncommon and rarely alters perfusion-diffusion mis-
match. Neurology 2010; 75:1040–7.
22 Sakamoto Y, Kimura K, Shibazaki K et al. Early ischaemic diffusion
lesion reduction in patients treated with intravenous tissue plasmino-
gen activator: infrequent, but significantly associated with recanaliza-
tion. Int J Stroke 2013; 8:321–6.
23 Labeyrie MA, Turc G, Hess A et al. Diffusion lesion reversal after
thrombolysis: a MR correlate of early neurological improvement.
Stroke 2012; 43:2986–91.
24 Campbell BCV, Purushotham A, Christensen S et al. The infarct core
is well represented by the acute diffusion lesion: sustained reversal is
infrequent. J Cereb Blood Flow Metab 2012; 32:50–6.
25 Li F, Liu KF, Silva MD et al. Transient and permanent resolution of
ischemic lesions on diffusion-weighted imaging after brief periods of
focal ischemia in rats: correlation with histopathology. Stroke 2000;
31:946–54.
26 Guadagno JV, Jones PS, Aigbirhio FI et al. Selective neuronal loss in
rescued penumbra relates to initial hypoperfusion. Brain 2008;
131:2666–78.
27 Tourdias T, Dousset V, Sibon I et al. Magnetization transfer imaging
shows tissue abnormalities in the reversible penumbra. Stroke 2007;
38:3165–71.
28 Purushotham A, Campbell BC, Straka M et al. Apparent diffusion
coefficient threshold for delineation of ischemic core. Int J Stroke 2013,
doi: 10.1111/ijs.12068.
29 An H, Ford AL, Vo K, Powers WJ, Lee JM, Lin W. Signal evolution and
infarction risk for apparent diffusion coefficient lesions in acute
ischemic stroke are both time- and perfusion-dependent. Stroke 2011;
42:1276–81.
30 Straka M, Albers GW, Bammer R. Real-time diffusion-perfusion mis-
match analysis in acute stroke. J Magn Reson Imaging 2010; 32:1024–
37.
31 Butcher K, Parsons M, Allport L et al. Rapid assessment of perfusion-
diffusion mismatch. Stroke 2008; 39:75–81.
32 Jones TH, Morawetz RB, Crowell RM et al. Thresholds of focal cere-
bral ischemia in awake monkeys. J Neurosurg 1981; 54:773–82.
33 Marchal G, Beaudouin V, Rioux P et al. Prolonged persistence of sub-
stantial volumes of potentially viable brain tissue after stroke: a cor-
relative PET-CT study with voxel-based data analysis. Stroke 1996;
27:599–606.
34 Hakim AM, Evans AC, Berger L et al. The effect of nimodipine on the
evolution of human cerebral infarction studied by PET. J Cereb Blood
Flow Metab 1989; 9:523–34.
35 Baron JC. Perfusion thresholds in human cerebral ischemia: historical
perspective and therapeutic implications. Cerebrovasc Dis 2001;
11(Suppl. 1):2–8.
36 Christensen S, Mouridsen K, Wu O et al. Comparison of 10 perfusion
MRI parameters in 97 sub-6-hour stroke patients using voxel-based
receiver operating characteristics analysis. Stroke 2009; 40:2055–61.
37 Zaro-Weber O, Moeller-Hartmann W, Heiss WD, Sobesky J. Maps of
time to maximum and time to peak for mismatch definition in clinical
stroke studies validated with positron emission tomography. Stroke
2010; 41:2817–21.
38 Nagakane Y, Christensen S, Ogata T et al. Moving beyond a single
perfusion threshold to define penumbra: a novel probabilistic mis-
match definition. Stroke 2012; 43:1548–55.
39 Olivot JM, Mlynash M, Zaharchuk G et al. Perfusion MRI (Tmax and
MTT) correlation with xenon CT cerebral blood flow in stroke
patients. Neurology 2009; 72:1140–5.
40 Christensen S, Campbell BCV, Perez de la Ossa N et al. Optimal per-
fusion thresholds for prediction of tissue destined for infarction in the
combined EPITHET and DEFUSE dataset. Stroke 2010; 41:e297.
41 Olivot JM, Mlynash M, Thijs VN et al. Optimal Tmax threshold for
predicting penumbral tissue in acute stroke. Stroke 2009; 40:469–75.
42 Campbell BCV, Christensen S, Tress BM et al. Failure of collateral
blood flow is associated with infarct growth in ischemic stroke. J. Cereb
Blood Flow and Metab 2013; 33:1168–72.
43 Christensen S, Parsons MW, De Silva DA et al. Optimal mismatch
definitions for detecting treatment response in acute stroke. Cerebro-
vasc Dis 2008; 25(Suppl. 2):33.
44 Kakuda W, Lansberg MG, Thijs VN et al. Optimal definition for PWI/
DWI mismatch in acute ischemic stroke patients. J Cereb Blood Flow
Metab 2008; 28:887–91.
45 Warach S, Al-Rawi Y, Furlan AJ et al. Refinement of the magnetic
resonance diffusion-perfusion mismatch concept for thrombolytic
patient selection: insights from the desmoteplase in acute stroke trials.
Stroke 2012; 43:2313–8.
46 Kidwell CS, Wintermark M, De Silva DA et al. Multiparametric MRI
and CT models of infarct core and favorable penumbral imaging
patterns in acute ischemic stroke. Stroke 2013; 44:73–9.
47 Kidwell CS, Jahan R, Gornbein J et al. A trial of imaging selection and
endovascular treatment for ischemic stroke. N Engl J Med 2013;
368:914–23.
48 Parsons MW, Albers GW. MR RESCUE: is the glass half-full or half-
empty? Stroke 2013; 44:2055–7.
49 Campbell BCV, Christensen S, Parsons MW et al. Advanced imaging
improves prediction of hemorrhage after stroke thrombolysis. Ann
Neurol 2013; 73:510–19.
50 Campbell BCV, Christensen S, Butcher KS et al. Regional very low
cerebral blood volume predicts hemorrhagic transformation better
than diffusion-weighted imaging volume and thresholded apparent
diffusion coefficient in acute ischemic stroke. Stroke 2010; 41:82–8.
51 Kim JH, Bang OY, Liebeskind DS et al. Impact of baseline tissue status
(diffusion-weighted imaging lesion) versus perfusion status (severity
ReviewB. C. V. Campbell and I. M. Macrae
© 2013 The Authors. International Journal of Stroke published by John Wiley & Sons Ltd
on behalf of World Stroke Organization.
Vol ••, •• 2013, ••–•• 9
of hypoperfusion) on hemorrhagic transformation. Stroke 2010;
41:e135–42.
52 Mlynash M, Lansberg MG, De Silva DA et al. Refining the definition of
the malignant profile: insights from the DEFUSE-EPITHET pooled
data set. Stroke 2011; 42:1270–5.
53 Planas AM. Noninvasive brain imaging in small animal stroke models:
MRI and PET; in Dirnagl U (ed.): Rodent Models of Stroke. Springer
Protocols Neuromethods 47. New York, Humana Press, 2010:139–65.
54 Traystman RJ. Effect of anaesthesia in stroke models; in Dirnagl U
(ed.): Rodent Models of Stroke. Springer Protocols Neuromethods 47.
New York, Humana Press, 2010:121–38.
55 Bulloch R, McCulloch J, Graham DI, Lowe D, Chen MH, Teasdale GM.
Focal ischemia in the cat: pre-treatment with a competitive NMDA
receptor antagonist, D-CPP-ene. J Cereb Blood Flow Metab 1990;
10:668–74.
56 Imai H, Konno K, Nakamura M et al. A new model of focal cerebral
ischaemia in the miniature pig. J Neurosurg 2006; 104:123–32.
57 Yonas H, Wolfson SK, Dujovny M, Boehnke M, Cook E. Selective
lenticulostriate occlusion in the primate. A highly focal cerebral isch-
emia model. Stroke 1981; 12:567–72.
58 Hesselbarth D, Franke C, Hata R, Brinker G, Hoehn-Berlage M. High
resolution MRI and MRS: a feasibility study for the investigation of
focal cerebral ischemia in mice. NMR Biomed 1998; 11:423–9.
59 Paul R, Zhang ZG, Eliceiri BP et al. Src deficiency or blockade of Src
activity in mice provides cerebral protection following stroke.NatMed
2001; 7:222–7.
60 Hughes PM, Allegrini PR, Rudin M, Perry VH, Mir AK, Wiessner C.
Monocyte chemoattractant protein-1 deficiency is protective in a
murine stroke model. J Cereb Blood Flow Metab 2002; 22:308–17.
61 Anderson SA, Frank JA. MRI of mouse models of neurological disor-
ders. NMR Biomed 2007; 20:200–15.
62 Hoehn-Berlage M, Hossmann KA, Busch E, Eis M, Schmitz B, Gyngell
ML. Inhibition of nonselective cation channels reduces focal ischemic
injury of rat brain. J Cereb Blood Flow Metab 1997; 17:534–42.
63 Li F, Han S, Tatlisumak T et al. A new method to improve in-bore
middle cerebral artery occlusion in rats: demonstration with
diffusion- and perfusion-weighted imaging. Stroke 1998; 29:1715–20.
64 Hoehn-Berlage M, Norris DG, Kohno K, Mies G, Leibfritz D,
Hossmann K-A. Evolution of regional changes in apparent diffusion
coefficient during focal ischemia of rat brain: the relationship of quan-
titative diffusion NMR imaging to reduction in cerebral blood flow
and metabolic disturbance. J Cereb Blood FlowMetab 1995; 5:1002–11.
65 Lo EH, Pierce AR, Mandeville JB, Rosen BR. Neuroprotection with
NBQX in rat focal cerebral ischemia. Effects on ADC probability dis-
tribution functions and diffusion–perfusion relationships. Stroke
1997; 28:439–47.
66 Li F, Carano RAD, Irie K, Sotak CH, Fisher M. Temporal evolution of
average apparent diffusion coefficient threshold to define ischemic
abnormalities in a rat permanent occlusion model. J Stroke Cerebro-
vasc Dis 2000; 9:1–7.
67 Shen Q, Meng X, Fisher M, Sotak CH, Duong TQ. Pixel-by-pixel
spatiotemporal progression of focal ischemia derived using quantita-
tive perfusion and diffusion imaging. J Cereb Blood Flow Metab 2003;
23:1479–88.
68 Meng X, Fisher M, Shen Q, Sotak CH, Duong TQ. Characterizing the
diffusion/perfusion mismatch in experimental focal cerebral ischemia.
Ann Neurol 2004; 55:207–12.
69 Reid E, Graham D, Lopez-Gonzalez MR, Holmes WM, Macrae IM,
McCabe C. Penumbra detection using PWI/DWI mismatch MRI in a
rat stroke model with and without co-morbidity: comparison of
methods. J Cereb Blood Flow Metab 2012; 32:1765–77.
70 Foley LM, Hitchens TK, Barbe B et al. Quantitative temporal profiles
of penumbra and infarction during permanent middle cerebral artery
occlusion in rats. Transl Stroke Res 2010; 1:220–9.
71 Letourneur A, Roussel S, Toutain J, Bernaudin M, Touzani O.
Impact of genetic and renovascular chronic arterial hypertension on
the acute spatiotemporal evolution of the ischemic penumbra: a
sequential study with MRI in the rat. J Cereb Blood Flow Metab 2011;
31:504–13.
72 Bardutzky J, Shen Q, Henninger N, Bouley J, Duong TQ, Fisher M.
Differences in ischemic lesion evolution in different rat strains using
diffusion and perfusion imaging. Stroke 2005; 36:2000–5.
73 Robertson C, McCabe C, Gallagher L et al. Stroke penumbra defined
by an MRI-based oxygen challenge technique: 1. Validation using
[14C]2-deoxyglucose autoradiography. J Cereb Blood FlowMetab 2011;
31:1778–87.
74 Robertson C, McCabe C, Gallagher L et al. Stroke penumbra defined
by an MRI-based oxygen challenge technique: 2. Validation based on
the consequences of reperfusion. J Cereb Blood Flow Metab 2011;
31:1788–98.
75 Bråtane BT, Bouley J, Schneider A, Bastan B, Henninger N, Fisher M.
Granulocyte-colony stimulating factor delays PWI/DWI mismatch
evolution and reduces final infarct volume in permanent-suture and
embolic focal cerebral ischemia models in the rat. Stroke 2009;
40:3102–6.
76 Bråtane BT, Cui H, Cook DJ, Bouley J, Tymianski M, Fisher M. Neu-
roprotection by freezing ischemic penumbra evolution without cere-
bral blood flow augmentation with a postsynaptic density-95 protein
inhibitor. Stroke 2011; 42:3265–70.
77 McCabe C, Gallagher L, Gsell W, Graham D, Dominiczak AF, Macrae
IM. Differences in the evolution of the ischaemic penumbra in the
SHRSP and WKY rat. Stroke 2009; 40:3864–8.
Review B. C. V. Campbell and I. M. Macrae
© 2013 The Authors. International Journal of Stroke published by John Wiley & Sons Ltd
on behalf of World Stroke Organization.
10 Vol ••, •• 2013, ••–••
